about
Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's diseasePositron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's diseaseEvidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup.Apolipoprotein E epsilon4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease.Early diagnosis of Alzheimer dementia based on clinical and biological factors.Outcome measures in Alzheimer's disease: do they go far enough?Mild cognitive impairment: a cross-national comparison.Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's diseaseImaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's diseaseClinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease.The effects of different familial Alzheimer's disease mutations on APP processing in vivo.Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment.Lexical and semantic ability in groups of children with cochlear implants, language impairment and autism spectrum disorder.Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease.Neuropsychiatric function of housepainters with previous long-term heavy exposure to organic solvents.Tone duration discrimination in demented, memory-impaired, and healthy elderly.A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.Prevalence and correlates of successful aging in a population-based sample of older adults: the HUNT study.Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.Health-adjusted neuropsychological test norms based on 463 older Swedish car drivers.Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.Reduced neuronal efficacy in progressive mild cognitive impairment: a prospective fMRI study on visuospatial processing.The importance of impaired physical health and age in normal cognitive aging.Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.Mild cognitive impairment--an early stage of Alzheimer's disease?Cognitive predictors of incident Alzheimer's disease: a prospective longitudinal study.Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages.Selective impact of disease on short-term and long-term components of self-reported memory: a population-based HUNT study.Amount and type of everyday technology use over time in older adults with cognitive impairment.Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease.Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
P50
Q28211806-F9A93634-3188-4BB4-A3F9-0F9414593219Q30497749-9F05470E-1758-47E7-8132-062A17E29B1EQ31074266-6C8AB539-751E-4D5E-BFD9-0F417399D252Q31112931-641C602D-8A34-4567-9CAD-89D329A23A3CQ31476991-E1A316C8-91C4-4D9D-B61E-115B47C9BF2AQ34022226-1DD0569D-8A20-4BD7-B70F-B9AC91D22118Q35483148-07D18A4B-F24D-4158-9BEB-4DCCDD31FDA9Q35868499-C623434E-3DDB-4897-AEC2-6E6D7DD71AC2Q36265825-333E93EA-30BC-4245-AE3D-320808E09FB0Q36434858-0ABB0296-78B5-4234-8A54-EB159533F2F9Q36615510-AD2DCD8F-7242-4EF6-B259-63A5EA44B7C4Q37063163-AAA8B962-FDE6-4F6F-A334-ED005D39722CQ37073096-4F11CF4D-847F-436C-9F88-3D81BBFA4BDAQ37294936-5800C84A-0589-465F-A0AE-24837F657622Q37297066-E7D7208B-118B-4235-AB2A-727231F1C556Q37645358-EB32F1AA-E2DD-4B38-8554-069F54716A67Q38427184-0C3AF30E-941A-4E18-9C86-CE6EA82542AFQ38439505-5968662D-177C-4D57-9000-63F702F2A786Q38449367-F6E2CC11-FD15-4AAA-A094-0609EDBF818BQ38509610-1B956D2F-8B9D-431C-9387-892CC09A5AA7Q38559758-BA0BA6AE-34AF-42EB-8BFC-32727D06D417Q38697140-9C296DB1-63D6-4F39-80D5-AEF5ABF883C8Q39182865-CE30B032-38FF-44D5-BD11-6ECBBC93B896Q39388222-B9F90D78-5545-400C-BDD0-041BBA47A611Q39945261-59A76DD2-A54F-440E-8415-90746AD50FEDQ39970942-6DEFF54C-40DC-4100-8329-CE66C4D17248Q40014398-E2F4537A-D941-4F35-9FE6-D59F2DF2D2E1Q40180351-21DA7039-AA88-4D5C-9FC5-A6C1FC16F7F0Q40223922-496DCE52-C0DA-4926-9E95-F471F3B4CBFBQ40716303-B0E25650-ED62-4667-AE3B-8C3851F59DDDQ40832054-D0C35EF8-05AD-42CE-BA20-F96556DA09CDQ40890205-BB177695-6FBC-4FAC-9A86-D3798E4A7260Q41064163-8A140444-95EB-450B-8D8A-A1D8F06C2C34Q41064163-D584A176-9D9D-467C-846E-C646D22EB1FFQ41485089-C467DAB8-FC7C-4493-BC60-7345ACBECAF8Q41593383-93ABFD80-2A00-4D66-AC8D-BA8C78C063C5Q42646408-AFB9DE57-05F8-4590-8E8E-0F5DE941A0D2Q43141731-A65EEC3B-E8D8-4856-BEDE-4F718DF4A38EQ43513247-CFA6F1BC-3533-44D7-B91D-2BA2110FCB97Q43737246-F02363E9-10F9-4C06-8EA0-9E4F93B9CEDF
P50
description
Zweeds onderzoeker
@nl
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Ove Almkvist
@ast
Ove Almkvist
@en
Ove Almkvist
@es
Ove Almkvist
@ga
Ove Almkvist
@nl
Ove Almkvist
@sl
Ove Almkvist
@sq
type
label
Ove Almkvist
@ast
Ove Almkvist
@en
Ove Almkvist
@es
Ove Almkvist
@ga
Ove Almkvist
@nl
Ove Almkvist
@sl
Ove Almkvist
@sq
prefLabel
Ove Almkvist
@ast
Ove Almkvist
@en
Ove Almkvist
@es
Ove Almkvist
@ga
Ove Almkvist
@nl
Ove Almkvist
@sl
Ove Almkvist
@sq
P106
P21
P27
P31
P496
0000-0003-0556-625X